arrow
M

Mark Carey

University of British Columbia
H指数:41
被引数:9,873

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Exploring patient and clinician perspectives for homologous recombination deficient (HRD) biomarker testing to guide precision medicine for advanced ovarian cancer treatment: a qualitative study

探索患者和临床医生对同源重组缺陷(HRD)生物标志物检测的视角,以指导晚期卵巢癌治疗的精准医学:一项定性研究

2026-10-100
OAAI
A scalable, multi-resolution consensus clustering approach for prioritizing robust signals from high-throughput screens

一种可扩展的多分辨率共识聚类方法,用于优先识别高通量筛选中的稳健信号

2026-05-240
OA
Establishment and characterization of preclinical models of human gynecologic tract carcinosarcomas demonstrates targetable FGFR1 alterations

建立和表征人类妇科 tract carcinosarcomas 的临床前模型表明存在可靶向的 FGFR1 突变

2025-11-060
OAAI
Molecular subtyping of endometrial carcinoma cell lines uncovers subtype-specific targetable vulnerabilities

子宫内膜癌细胞的分子分型揭示了分型特异的可靶向易损性

2025-07-240
OAAI
The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative

Terry Fox Research Institute马拉松希望癌症中心网络:一项全加拿大的精准肿瘤学倡议

2025-04-010
PRE
NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition
2022-10-057
OAAI
Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression
2022-06-2914
OAAI
Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability
2021-01-1329
OA
Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities

低级别浆液性卵巢癌的基因组分析,以确定关键驱动因素和治疗脆弱性

2020-10-2869
OAAI
BRCA1 Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis
2020-05-1538
OAAI